beta

A

Agilent Technologies Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Market Cap: 38.2 Billion

Primary Exchange: NEW YORK STOCK EXCHANGE, INC.

Website: https://www.agilent.com/

Shares Outstanding: 307 Million

Float: 0

Dividend: 0.732093164670622 (0.01%)

Beta: 0.905793440164726

Sector: Professional, Scientific, and Technical Services

Industry: Testing Laboratories

Ethical Flags

Longest drawdown: 874 trading days

From: 2014-01-22 To: 2017-07-12

Lowest Point:

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

via: Business Wire at 2019-06-11 03:56:00:000

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

via: Business Wire at 2019-06-11 03:56:00:000

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

via: Business Wire at 2019-06-11 03:56:00:000

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2021-01-04 2021-01-27 2021-01-05 2020-11-18 0.194000005722046 Cash
2020-10-05 2020-10-28 2020-10-06 2020-09-16 0.18 Cash
2020-06-29 2020-07-22 2020-06-30 2020-05-20 0.18 Cash
2020-03-30 2020-04-22 2020-03-31 2020-03-18 0.18 Cash
2019-12-30 2020-01-22 2019-12-31 2019-11-20 0.18 Cash
2019-09-30 2019-10-23 2019-10-01 2019-09-18 0.164 Cash
2019-09-30 2019-10-23 2019-10-01 2019-09-18 0.164 No Change QoQ
2019-07-01 2019-07-24 2019-07-02 2019-05-22 0.164 No Change QoQ
2019-04-01 2019-04-24 2019-04-02 2019-03-20 0.164 No Change QoQ
2018-12-28 2019-01-23 2018-12-31 2018-11-14 0.164 Increase
2018-10-01 2018-10-24 2018-10-02 2018-09-19 0.149 No Change QoQ
2018-07-02 2018-07-25 2018-07-03 2018-05-16 0.149 No Change QoQ
2018-04-02 2018-04-25 2018-04-03 2018-03-21 0.149 No Change QoQ
2017-12-29 2018-01-24 2018-01-02 2017-11-15 0.149 Increase
2017-10-02 2017-10-25 2017-10-03 2017-09-20 0.132 No Change QoQ
2017-06-29 2017-07-26 2017-07-03 2017-05-17 0.132 No Change QoQ
2017-03-31 2017-04-26 2017-04-04 2017-03-15 0.132 No Change QoQ
2016-12-29 2017-01-25 2017-01-03 2016-11-17 0.132 Increase
2016-09-30 2016-10-26 2016-10-04 2016-09-21 0.115 No Change QoQ
2016-06-30 2016-07-27 2016-07-05 2016-05-18 0.115 No Change QoQ
2016-04-01 2016-04-27 2016-04-05 2016-03-16 0.115 No Change QoQ
2015-12-31 2016-01-27 2016-01-05 2015-11-19 0.115 Increase
2015-09-25 2015-10-21 2015-09-29 2015-09-16 0.1 No Change QoQ
2015-06-26 2015-07-22 2015-06-30 2015-05-20 0.1 No Change QoQ
2015-03-27 2015-04-22 2015-03-31 2015-03-18 0.1 No Change QoQ
2015-01-02 2015-01-28 2015-01-06 2014-11-20 0.1 Decrease
2014-09-26 2014-10-22 2014-09-30 2014-09-17 0.132 No Change QoQ
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud